Seven IPOs raised $1.1 billion, an active week given the market's volatility. Reflecting that backdrop, five of the seven five priced below the range, and two more postponed. Most had insider support. While the number of deals on the ...read more
PhaseBio Pharmaceuticals, a Phase 2 biotech developing therapies for rare cardiopulmonary diseases, raised $46 million by offering 9.2 million shares (vs. 5.0 million originally) at $5, below the range of $12 to $14. PhaseBio Pharmaceuticals plans to list on the...read more
Eight IPOs plan to raise $1.6 billion in the week ahead. Tech, biotech and China have been key drivers of 2018 IPO activity, and more of each are scheduled for the week ahead. Each of the three segments was hit particularly hard during the recent sell-off, but...read more
PhaseBio Pharmaceuticals, an early-stage biotech developing therapies to treat orphan diseases, announced terms for its IPO on Friday. The Malvern, PA-based company plans to raise $65 million by offering 5 million shares at a price range of $12 to $14....read more
US IPO Weekly Recap: IPOs are put through the ringer with 7 completed deals
Seven IPOs raised $1.1 billion, an active week given the market's volatility. Reflecting that backdrop, five of the seven five priced below the range, and two more postponed. Most had insider support. While the number of deals on the ...read more
PhaseBio Pharmaceuticals prices IPO at $5, below the range
PhaseBio Pharmaceuticals, a Phase 2 biotech developing therapies for rare cardiopulmonary diseases, raised $46 million by offering 9.2 million shares (vs. 5.0 million originally) at $5, below the range of $12 to $14. PhaseBio Pharmaceuticals plans to list on the...read more
US IPO Week Ahead: SolarWinds headlines 8-IPO week with tech, biotech and China
Eight IPOs plan to raise $1.6 billion in the week ahead. Tech, biotech and China have been key drivers of 2018 IPO activity, and more of each are scheduled for the week ahead. Each of the three segments was hit particularly hard during the recent sell-off, but...read more
Orphan disease biotech PhaseBio Pharmaceuticals sets terms for $65 million IPO
PhaseBio Pharmaceuticals, an early-stage biotech developing therapies to treat orphan diseases, announced terms for its IPO on Friday. The Malvern, PA-based company plans to raise $65 million by offering 5 million shares at a price range of $12 to $14....read more